TYRA

+ Watchlist + Portfolio

Tyra Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.81
52-Week Range: $9.97 – $40.65
Market Cap: $1.53B
P/E (TTM): —
EPS (TTM): -2.29
Dividend Yield: —

Advanced Metrics

Price/Book: 5.32
PEG Ratio: —
Return on Equity: -45.31%
Return on Assets: -28.46%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 14.90
Debt/Equity: 0.02
Total Debt: $5.58M
Free Cash Flow: $-63.07M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.18B

TYRA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$43.01M	$62.52M	$80.08M	$102.93M
Selling, General & Admin	$15.92M	$17.43M	$24.10M	$29.83M
Operating Expenses	$58.93M	$79.94M	$104.18M	$132.76M
Operating Income	-$58.93M	-$79.94M	-$104.18M	-$132.76M
EBITDA	-$58.63M	-$79.59M	-$103.66M	-$132.22M
Pretax Income	-$55.33M	-$69.13M	-$86.48M	-$119.95M
Net Income	-$55.33M	-$69.13M	-$86.48M	-$119.95M
Diluted EPS	-1.32	-1.62	-1.51	-2.01
Diluted Shares	41.88M	42.70M	57.22M	59.60M

TYRA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$251.21M	$58.01M	$91.97M	$77.39M
Current Assets	$257.29M	$211.67M	$347.46M	$265.45M
Total Assets	$266.18M	$225.86M	$363.56M	$282.61M
Current Liabilities	$5.70M	$15.33M	$14.59M	$18.09M
Total Debt	$2.62M	$6.50M	$6.22M	$5.81M
Total Liabilities	$8.35M	$21.59M	$20.41M	$23.43M
Retained Earnings	-$95.70M	-$164.83M	-$251.31M	-$371.26M
Shareholders' Equity	$257.83M	$204.26M	$343.15M	$259.18M
Working Capital	$251.59M	$196.34M	$332.87M	$247.36M

TYRA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$50.28M	-$50.14M	-$69.77M	-$95.14M
Capital Expenditure	-$559.00K	-$770.00K	-$664.00K	-$141.00K
Free Cash Flow	-$50.84M	-$50.91M	-$70.44M	-$95.28M
Depreciation & Amortisation	$296.00K	$357.00K	$519.00K	$546.00K
Stock-Based Compensation	$10.59M	$13.53M	$22.80M	$28.01M
Investing Cash Flow	-$559.00K	-$144.60M	-$98.40M	$72.46M
Financing Cash Flow	$632.00K	$1.54M	$202.14M	$8.10M
Share Repurchases	—	$0.00	-$420.00K	$0.00
Net Change in Cash	-$50.21M	-$193.21M	$33.96M	-$14.58M

TYRA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$24.96M	$24.31M	$25.47M	$28.19M	$33.47M
Selling, General & Admin	$6.89M	$7.14M	$7.47M	$8.33M	$8.53M
Operating Expenses	$31.85M	$31.45M	$32.94M	$36.52M	$42.00M
Operating Income	-$31.85M	-$31.45M	-$32.94M	-$36.52M	-$42.00M
EBITDA	-$31.71M	-$31.31M	-$32.81M	-$36.38M	-$41.86M
Pretax Income	-$28.15M	-$28.10M	-$29.87M	-$33.83M	-$39.30M
Net Income	-$28.15M	-$28.10M	-$29.87M	-$33.83M	-$39.30M
Diluted EPS	-0.47	-0.47	-0.50	-0.57	-0.64
Diluted Shares	59.34M	59.55M	59.67M	59.83M	61.75M

TYRA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$100.72M	$98.49M	$61.95M	$77.39M	$84.95M
Current Assets	$324.57M	$302.15M	$281.22M	$265.45M	$394.61M
Total Assets	$343.48M	$321.50M	$301.85M	$282.61M	$412.04M
Current Liabilities	$14.25M	$13.77M	$15.88M	$18.09M	$19.26M
Total Debt	$6.12M	$6.02M	$5.92M	$5.81M	$5.70M
Total Liabilities	$19.94M	$19.35M	$21.34M	$23.43M	$24.46M
Retained Earnings	-$279.46M	-$307.56M	-$337.42M	-$371.26M	-$410.56M
Shareholders' Equity	$323.53M	$302.15M	$280.51M	$259.18M	$387.57M
Working Capital	$310.32M	$288.38M	$265.34M	$247.36M	$375.36M

TYRA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$25.46M	-$23.68M	-$22.38M	-$23.62M	-$32.57M
Capital Expenditure	-$14.00K	-$31.00K	-$39.00K	-$57.00K	-$88.00K
Free Cash Flow	-$25.47M	-$23.71M	-$22.42M	-$23.68M	-$32.66M
Depreciation & Amortisation	$143.00K	$140.00K	$131.00K	$132.00K	$138.00K
Stock-Based Compensation	$6.42M	$6.38M	$7.58M	$7.63M	$7.85M
Investing Cash Flow	$32.03M	$20.87M	-$14.81M	$34.38M	-$120.24M
Financing Cash Flow	$2.19M	$583.00K	$647.00K	$4.68M	$160.38M
Share Repurchases	$0.00	$0.00	$0.00	$0.00	—
Net Change in Cash	$8.76M	-$2.23M	-$36.54M	$15.44M	$7.57M

Market Snapshot

About

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptors (FGFRs). The company is advancing a pipeline of selective FGFR inhibitors designed to treat patients with cancer and other serious diseases. Tyra utilizes its proprietary SNÅP platform to design highly selective kinase inhibitors.